Analysten nachrichten

South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)

External page is loading, the page should display in a few seconds..

    Follow @AnalystenNews on Twitter!